Bottom line
Is IXJ a good fund? The bottom line
IXJ is an actively managed health care sector ETF from iShares.
Its expense ratio is 0.38% — about $38 a year on every $10,000 invested, cheaper than 87% of health care sector funds we track.
It returned +14.9% over one year, +6.4% a year over five years, +8.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $3.8 billion in net assets and 124 holdings, its largest position is Eli Lilly And Company (10.9%) and the top 10 make up 47.8% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 76% top-holdings overlap).
What stands out
- Low cost: cheaper than 87% of health care sector peers
- 5-year return beat 75% of category peers
Updated Nov 19, 2026
What IXJ invests in
The iShares Global Healthcare ETF (the Fund ) seeks to track the investment results of an index composed of global equities in the healthcare sector.
The Fund seeks to track the investment results of the S&P Global 1200 Health Care (Sector) Capped Index TM (the Underlying Index ), which measures the performance of companies that S&P Dow Jones Indices LLC (the Index Provider or SPDJI ), a subsidiary of S&P Global, Inc., deems to be a part of the healthcare sector of the economy and that SPDJI believes are important to global markets. The Underlying Index is a subset of the S&P Global 1200, which is designed to measure the performance of large-capitalization stocks from major global markets, as determined by SPDJI. As of March 31, 2026, a significant portion of the Underlying Index was represented by securities of companies in the healthcare industry or sector. The components of the Underlying Index are likely to change over time. As of March 31, 2026, the Underlying Index was composed of securities of companies in the following…
From the fund's prospectus (filed Jul 27, 2026).
IXJ performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| IXJ | +14.9% | +6.4% | +8.2% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What IXJ costs
On a $10,000 investment, IXJ's 0.38% expense ratio costs about $38 a year. The prospectus estimates $480 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
IXJ top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly And Company | 10.93% |
| 2 | Johnson & Johnson | 7.04% |
| 3 | Abbvie Inc. | 5.12% |
| 4 | Unitedhealth Group Incorporated | 4.40% |
| 5 | Merck & Co., Inc. | 4.12% |
| 6 | Astrazeneca Plc | 3.76% |
| 7 | Roche Holding AG | 3.75% |
| 8 | Novartis AG | 3.71% |
| 9 | Amgen Inc. | 2.54% |
| 10 | Thermo Fisher Scientific Incorporated | 2.42% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 47.8% of the fund. See all top 25 holdings and asset mix →
Alternatives to IXJ
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 76% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 76% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 78% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 68% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 76% | Compare |
| T. Rowe Price | PRHSX T. Rowe Price Health Sciences Fund, Inc. | 0.83% | 70% | Compare |